尿道感染藥物市場：依藥物、適應症及地區分類

Urinary Tract Infection Therapeutic Market, By Drug, By Indication, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

出版日期: 2025年03月03日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球尿道感染藥物市場規模估計為 94 億美元，預計到 2032 年將達到 117.1 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 3.20%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	94億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	3.20%	2032年價值預測	117.1億美元

數字。 2025年尿道感染治療市場佔有率（按地區）

尿道感染（UTI）是泌尿器官系統任何部位的感染疾病。女性罹患尿道感染的風險高於男性。尿道感染(UTI) 通常由糞便中的細菌進入尿道所引起。尿道感染的首要治療方法通常是抗生素。常用於治療無併發症的尿道感染的藥物包括甲氧芐啶-磺胺甲噁唑（Bactrim、Bactrim DS）、磷黴素（Monurol）、呋喃妥因（Macrodantin、Macrobid、Furadantin）、頭孢氨芐和頭孢曲松。

市場動態：

尿道感染盛行率高、糖尿病和腎結石盛行率上升、老年人口成長以及對新型治療劑開發的日益關注是預測期內推動全球尿道感染藥物市場成長的關鍵因素。

2021年10月，Spero Therapeutics Inc.向美國食品藥物管理局（USFDA）提交了新藥認證（NDA），尋求核准氫溴酸替比培南片用於治療由敏感微生物引起的複雜性尿道感染（cUTI），包括腎盂腎炎。此外，2021年9月，我們推出了Viapenem，用於治療腹腔內感染疾病、下呼吸道感染疾病和複雜性尿道感染。

2020年7月，美國食品藥物管理局（FDA）核准抗生素Recarbrio（Imipenem、西司他丁、瑞利巴坦）用於治療成人複雜性尿道感染（cUTI）及複雜性腹腔內感染疾病（cIAI）。

本研究的主要特點

本報告對全球尿道感染治療市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和復合年成長率。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
該報告涵蓋了全球尿道感染藥物市場的主要企業概況，基於以下參數，例如公司亮點、產品系列、主要亮點、績效和策略。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球尿道感染藥物市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
可以透過用於分析全球尿道感染藥物市場的各種策略矩陣來促進相關人員的決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 9.4 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	3.20%	2032 Value Projection:	USD 11.71 Bn

A urinary tract infection (UTI) is an infection in any part of the urinary system. Women are at greater risk of developing a urinary tract infection compared to men. Urinary tract infections (UTIs) are usually caused by bacteria from poo entering the urinary tract. Antibiotics usually are the first treatment for urinary tract infections. Medicines commonly used for simple UTI s include Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS), Fosfomycin (Monurol), Nitrofurantoin (Macrodantin, Macrobid, and Furadantin), Cephalexin, and Ceftriaxone.

Market Dynamics:

High prevalence of urinary tract infection, increasing prevalence of diabetes and kidney stones, increasing geriatric population, and increase in focus on the development of novel therapeutics are some major factors expected to drive growth of the global urinary tract infection therapeutic market during the forecast period.

In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Moreover, in September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

In July 2020, the U.S. Food and Drug Administration (FDA) approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Key features of the study:

This report provides in-depth analysis of the global urinary tract infection therapeutic market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global urinary tract infection therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global urinary tract infection therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary tract infection therapeutic market.

Detailed Segmentation:

Global Urinary Tract Infection Therapeutic Market By Drug:
- Penicillin and Combinations
- Quinolones
- Cephalosporin
- Azoles and Amphotericin B
- Nitrofurans
- Other Drugs
Global Urinary Tract Infection Therapeutic Market By Indication;
- Complicated UTI
- Uncomplicated UTI
- Other Indications
Global Urinary Tract Infection Therapeutic Market By Geography:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Pfizer
- Novartis AG
- Cipla Inc.
- Bayer AG
- AstraZeneca
- Shionogi & Co. Ltd.
- GlaxoSmithKline PLC

Market Dynamics
- High prevalence of urinary tract infection across the globe
- Adverse effects associated with the use of UTI medication
- Increase in focus on the development of novel drugs
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Urinary Tract Infection Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Urinary Tract Infection Therapeutic Market, By Drug, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Penicillin and Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Quinolones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Azoles and Amphotericin B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Nitrofurans
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Other Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Urinary Tract Infection Therapeutic Market, By Indication, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Complicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Uncomplicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Urinary Tract Infection Therapeutic Market, By Geography, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)

8. Competitive Landscape

Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Shionogi & Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies